Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers

Trial Profile

Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs BIIB 063 (Primary)
  • Indications Sjogren's syndrome
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Biogen
  • Most Recent Events

    • 17 Apr 2017 Status changed from suspended to discontinued due to pending additional preclinical safety findings in non-human primates.
    • 24 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
    • 24 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top